ArticleBMJ open2025

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

Matthias Augustin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.